Figure 2
MMPI (A-177430) and COX-2I (A-285969) cooperate to reduce tumour multiplicity in Min mice. Single-dose study (A) involved treatment of Min mice at 5–6 weeks for 45 days with twice daily i.p. injections of vehicle (HPMC, n=3), a broad-spectrum MMPI (A-177430, n=6), a COX-2I (A-285969, n=5), or an NSAID (sulindac, n=6) at the doses indicated. *Denotes statistically significant difference between individual treatment groups and the vehicle-treated group. Combination study (B) repeated the above regimen using suboptimal doses alone and in combination as indicated. Each bar is representative of the total number of mice in the experiment where vehicle n=5, COX-2I n=5, MMPI n=6, and combination n=6. Statistical differences were calculated as described in Materials and Methods by comparing vehicle and treated groups *P=0.0367, **P=0.009, ***P=0.0062 or the combination-treated group and individual treatment groups. ‡P=0.0062. Tumour size (C) was determined as described in Materials and Methods.
